NV-WEJO-GROUP
4.1.2022 22:32:08 CET | Business Wire | Press release
Wejo Group Limited (NASDAQ: WEJO), a global leader in cloud and software analytics generated from AV, EV and connected vehicle data (CVD), today announced it is developing a breakthrough Wejo Neural EdgeTM platform that will enable intelligent handling of data from vehicles at scale, while providing incredible insights that protect privacy and empower automotive innovation. In partnership with Microsoft, Wejo will make the announcement virtually from the Microsoft Partners Pavilion at the Consumer Electronics Show in Las Vegas.
With so much rich data coming from vehicles today, latency and data storage costs are potential obstacles in harnessing and scaling the power of real-time vehicle communications - both with other vehicles and the infrastructure that is set to power Smart Cities. Leveraging our strategic partnership with Microsoft Azure and powered by Wejo’s ADEPT platform, Wejo Neural EdgeTM optimizes how this data is managed within the vehicle, further processes it at the Edge and ultimately communicates to the cloud. This process will not only reduce data overload and maximize data insights but will reduce costs for automotive manufacturers and improve manufacturing of the vehicle to provide a better driving experience – supporting safer vehicles, enabling further advancements in EV and autonomous mobility, and reducing congestion and emissions.
“When I started Wejo in 2014, I knew that the proliferation of new mobility technology would drive data to a tipping point. And we are at that point today,” said Richard Barlow, Founder & CEO, Wejo. “With today’s vehicles producing approximately 25 gigabytes of data per hour, and as vehicle technology advances adding more sensors, data filtering and neural edge processing technology is essential to reduce this overload and drive the industry forward. Partnering with Microsoft and Palantir has positioned us to address this problem today, and to look ahead at the benefits of Wejo Neural EdgeTM as a driver in the growth of autonomous mobility. “
Wejo Neural EdgeTM will filter and analyze vast amounts of AV, EV and CV data before transmitting only the essential information to the cloud. This is made possible by utilizing in-car edge processing that Wejo is developing to filter only useful and valuable CVD before it is transmitted to the cloud. The embedded software technology in combination with Microsoft Azure cloud computing platform will enable Wejo Neural EdgeTM to power automotive innovation by:
- Reducing network and storage costs for the auto manufacturers by optimising the data coming from the vehicle. Leveraging embedded software within the vehicle chipset, Wejo Neural EdgeTM is designed to intelligently choose and prioritize the data to be sent from the vehicle to the cloud.
- Utilizing machine learning algorithms to reconstruct vehicle journey and event data, Wejo Neural EdgeTM can take 20% of the data from autonomous, electric, and other connected vehicles and reconstruct it to represent 100% of the data, without any loss in data fidelity or integrity. The positive environmental impact is significant, as less data requires less storage which in turn reduces power consumption.
- Enabling Vehicle to Vehicle (V2V) and Vehicle to Infrastructure (V2X) communications. Wejo Neural EdgeTM enables the standardisation and centralisation of the data that comes from autonomous, electric and connected vehicles. Not only does this provide a key building block for communication in near real time, but it also supports communication with infrastructure services such as road signs, traffic lights and parking lots, so vehicles can easily anticipate the road ahead and optimise mobility experiences.
- Delivering a digital twin of the vehicle and cities to reshape how we view the entire product and service ecosystem related to mobility. In a simulation environment, a digital twin of the US can be constructed to simulate how vehicles in different cities need to respond and navigate without having to outlay massive infrastructure costs of physical hardware or vehicles to be able to relearn how a vehicle should behave as an AV or EV, in the Smart City, etc.
“At Wejo, we believe that digital twins will reshape everything from road safety, to insurance, advertising, after-sales and more,” said David Burns, Chief Technology Officer, Wejo. “With Wejo Neural Edge we can look at what a CV is doing a kilometer away, and then alter and change the driver experience of an AV based on the information that is coming from down the road.”
As more auto manufacturers work to harness their vehicle data, Wejo Neural EdgeTM and Wejo’s common data model will enable different manufacturer makes and models to speak the same data language, a key component supporting vehicle to vehicle communication and vehicle communications with infrastructure and services. Wejo’s continued partnership with Palantir furthers how this model can adeptly address the problems of today and inform decisions for tomorrow.
“Our ongoing partnership with Wejo is focused on the most complex and critical challenges facing the future of mobility” says Shyam Sankar, Chief Operating Officer of Palantir Technologies. “What Wejo is building atop Palantir Foundry, including their cutting-edge neural edge technology, is a testament to the depth of their vision, speed of execution, and power of combining our technologies.”
Further details about the availability of the Wejo Neural Edge Processing platform will come at a future date.
About Wejo
Wejo (NASDAQ: WEJO) is a global leader in connected vehicle data, revolutionising the way we live, work and travel by transforming and interpreting historic and real-time vehicle data. The company enables smarter mobility by organising trillions of data points from 11.9 million vehicles and more than 60 billion journeys globally, across multiple brands, makes and models, and then standardising and enhancing those streams of data on a vast scale. Wejo partners with ethical, like-minded companies and organisations to turn that data into insights that unlock value for consumers. With the most comprehensive and trusted data, information and intelligence, Wejo is creating a smarter, safer, more sustainable world for all. Founded in 2014, Wejo employs more than 250 people and has offices in Manchester in the UK and in regions where Wejo does business around the world. For more information, visit: www.wejo.com .
About Palantir
Palantir Technologies Inc. builds and deploys operating systems for the modern enterprise. Additional information is available at https://www.palantir.com .
Who dares, wins.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this release, including statements regarding the Company’s future operating results and financial position, business strategy and plans, objectives of management for future operations are forward-looking statements. These statements are based on the Company’s current expectations, assumptions, estimates and projections. These statements involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements are based on management's current expectations and assumptions regarding the Company’s business, the economy and other future conditions.
Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those factors described in the Company’s filings with the Securities and Exchange Commission.
These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially, and potentially adversely, from those expressed or implied in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (i) the impact of the COVID-19 pandemic on the Company’s business; (ii) the inability to obtain or maintain the listing of the Company’s common shares on the Nasdaq Stock Market following the business combination; (iii) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth profitably, and retain its key employees; (iv) changes in applicable laws or regulations; (v) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, and (vi) the company’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in Wejo’s Form 10-Q for the period ended September 30, 2021 and Wejo’s most recent filings with the SEC. All readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104006003/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
